---
title: "Sabra Health Care REIT Inc. Enters Equity Distribution Agreement with Multiple Financial Institutions"
description: "Sabra Health Care REIT, Inc. has entered into an equity distribution agreement with financial institutions including Barclays, BMO Capital Markets, and Morgan Stanley. Established on August 5, 2025, t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251709841.md"
published_at: "2025-08-05T21:17:15.000Z"
---

# Sabra Health Care REIT Inc. Enters Equity Distribution Agreement with Multiple Financial Institutions

> Sabra Health Care REIT, Inc. has entered into an equity distribution agreement with financial institutions including Barclays, BMO Capital Markets, and Morgan Stanley. Established on August 5, 2025, the agreement allows for the sale of common stock to repay debts, fund investments, and for corporate purposes. The consortium will manage the sales, with potential agent compensation up to $11.25 million. The company also terminated a previous agreement from February 2023 for up to $500 million in stock sales.

Sabra Health Care REIT, Inc. has entered into a new equity distribution agreement with a consortium of financial institutions, including major players such as Barclays Capital Inc., BMO Capital Markets Corp., and Morgan Stanley & Co. LLC. This agreement, established on August 5, 2025, allows for the sale of shares of the company’s common stock, with proceeds intended for repaying debts, funding future investments, and general corporate purposes. The sales will be managed by the consortium, with an aggregate compensation for agents potentially reaching up to $11.25 million. The company also terminated a prior distribution agreement from February 2023 that allowed for up to $500 million in stock sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sabra Health Care REIT Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-173630), on August 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SBRA.US - Sabra Healthcare Reit](https://longbridge.com/en/quote/SBRA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sabra Healthcare REIT: Solid SHOP Momentum Offset by Soft FFO Outlook and RCA Loan Uncertainty Supports Hold Rating | Sabra Healthcare REIT received a Hold rating from BMO Capital analyst Juan C. Sanabria, with a price target of $22.00. T | [Link](https://longbridge.com/en/news/275841415.md) |
| Sabra Health Care REIT Inc. published an update to their financial calendar | Sabra Health Care REIT, Inc. will release its Q4 2025 earnings on February 12, 2026, after market close. A conference ca | [Link](https://longbridge.com/en/news/274557759.md) |
| Sabra Health Care REIT Inc. Files Initial Statement of Beneficial Ownership for Darrin Smith, Executive VP, CIO & Secretary | Sabra Health Care REIT Inc. has filed an initial statement of beneficial ownership (Form 3) with the SEC, identifying Da | [Link](https://longbridge.com/en/news/272334430.md) |
| Jefferies Keeps Their Buy Rating on Sabra Healthcare REIT (SBRA) | Jefferies analyst maintained a Buy rating on Sabra Healthcare REIT today and set a price target of $22.00.Claim 50% Off  | [Link](https://longbridge.com/en/news/269776403.md) |
| Sabra Healthcare REIT: Balancing Strong FAD Performance with Capital Cost Challenges | Juan C. Sanabria has assigned a Hold rating to Sabra Healthcare REIT, citing mixed performance in its third-quarter 2025 | [Link](https://longbridge.com/en/news/264519606.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.